Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy.
Thomas Walter GeorgiLars KurchGeorg-Nikolaus FrankeMadlen JentzschSebastian SchwindCarmen Perez-FernandezNaima PetermannMaximilian MerzKlaus H MetzelerGudrun BorteSandra HoffmannMarco HerlingTimm DeneckeRegine KlugeOsama SabriUwe PlatzbeckerVladan VucinicPublished in: Journal of cancer research and clinical oncology (2023)
Our results confirm the prognostic value of PET-1. 42% of all CMR patients are still in remission 1 year after CAR T-cell treatment. 90% of the non-CMR patients relapsed, indicating the need for early intervention. Higher TMTV before CAR-T cell infusion was associated with lower chances of CMR.